

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

(Present Status of Competition in the Pharmaceutical Industry)

THURSDAY, FEBRUARY 21, 1974

U.S. SENATE,
SUBCOMMITTEE ON MONOPOLY OF THE
SELECT COMMITTEE ON SMALL BUSINESS,
Washington, D.C.

The subcommittee met, pursuant to notice, at 10:15 a.m., in room 6202, Dirksen Senate Office Building, Senator Gaylord Nelson [chairman of the subcommittee] presiding.

Present: Senator Nelson.

Also present: Chester H. Smith, Staff Director and General Counsel; Benjamin Gordon, Staff Economist; and John O. Adams, Minority Counsel.

Senator NELSON. Our first witness this morning will be Dr. William Apple, Executive Director of the American Pharmaceutical Association.

You may go ahead and present your statement. The committee is very pleased to have you here this morning.¹

STATEMENT OF DR. WILLIAM S. APPLE, EXECUTIVE DIRECTOR OF THE AMERICAN PHARMACEUTICAL ASSOCIATION, ACCOMPANIED BY DR. EDWARD G. FELDMANN, ASSOCIATE EXECUTIVE DIRECTOR FOR SCIENTIFIC AFFAIRS; AND CARL ROBERTS, COUNSEL

Dr. APPLE. Thank you, Mr. Chairman. I am Dr. William S. Apple, Executive Director of the American Pharmaceutical Association. I am accompanied by Dr. Edward G. Feldmann, Associate Executive Director for Scientific Affairs, and our Counsel, Mr. Carl Roberts.

Before Dr. Feldmann presents our specific comments on the subject matter requested in your invitation for APhA testimony, we feel that it is most important first to make the following general comments.

Senator Nelson, APhA wants the Congress to know that no one has a greater interest than the pharmacist in clearing up the doubts and suspicions that have been propagated in an obviously organized campaign questioning the safety and integrity of prescription drugs

¹ See information beginning at page 10724.